BRD4-TARGETED THERAPY ABBV-744 CLINICAL DATA NO FURTHER A MYSTERY

The current work examined the potential of utilizing ARV-825 and ABBV-744 to improve the effectiveness of tamoxifen or fulvestrant plus palbociclib. ARV-825 was effective in both equally p53 wild-type (WT) breast tumor cells and in cells lacking practical p53 both on your own or in combination with tamoxifen, though the effectiveness of ABBV-744 wa